Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Aurinia Pharmaceuticals (GB:0UJF)
LSE:0UJF
Aurinia Pharmaceuticals (GB:0UJF) Stock Price & Analysis
0 Followers
0UJF Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$15.41 - C$15.41
Previous CloseC$15.41
Volume0.00
Average Volume (3M)N/A
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$391.74M
Total Debt (Recent Filing)$8.38M
Price to Earnings (P/E)-14.6
Beta0.90
Next EarningsMar 09, 2023
EPS Estimate-C$0.36
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetC$15.76
EPS (TTM)-1.05
Shares Outstanding128,225,927
R-Squared0.03
Standard Deviation0.34
10 Day Avg. Volume5,313
30 Day Avg. VolumeN/A
Price to Book (P/B)2.71
Price to Sales (P/S)29.13
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-12.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside2.26% Upside
Rating ConsensusStrong Buy
Alpha0.07
Number of Analyst Covering5
Aurinia Pharmaceuticals News
0UJF FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was C$15.41 and its highest was C$15.41 in the past 12 months.
What is Aurinia Pharmaceuticals’s market cap?
Currently, no data Available
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
Aurinia Pharmaceuticals’s upcoming earnings report date is Mar 09, 2023 which is in 41 days.
How were Aurinia Pharmaceuticals’s earnings last quarter?
Aurinia Pharmaceuticals released its earnings results on Nov 03, 2022. The company reported -C$0.08 earnings per share for the quarter, beating the consensus estimate of -C$0.309 by C$0.229.
Is Aurinia Pharmaceuticals overvalued?
According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued.
Does Aurinia Pharmaceuticals pay dividends?
Aurinia Pharmaceuticals does not currently pay dividends.
What is Aurinia Pharmaceuticals’s EPS estimate?
Aurinia Pharmaceuticals’s EPS estimate is -C$0.36.
How many shares outstanding does Aurinia Pharmaceuticals have?
Aurinia Pharmaceuticals has 142,109,700 shares outstanding.
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Aurinia Pharmaceuticals reported an EPS of -C$0.08 in its last earnings report, beating expectations of -C$0.309. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
Among the largest hedge funds holding Aurinia Pharmaceuticals’s share is Gilder Gagnon Howe & Co LLC.. It holds Aurinia Pharmaceuticals’s shares valued at 1M.
---
Aurinia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$15.76
C$15.76
Blogger Sentiment
Bullish
GB:0UJF Sentiment 66%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $406.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Positive
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.38%
12-Months-Change
Fundamentals
Return on Equity
-32.00%
Trailing 12-Months
Asset Growth
35.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
---
---